Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma

Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Collaboration Includes Additional Select Advanced Solid Tumors THOUSAND OAKS, Calif. and KENILWORTH, N.J. – Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen’s CD19 bispecific T cell engager (BiTE®), and KEYTRUDA is Merck’s anti-PD-1 antibody. Language: English read more
Source: Merck - Category: Pharmaceuticals Source Type: news